Friday, July 17, 2026
🇺🇸 FDA

QA/QC Tools · OOS · FDA Guidance · GMP · ICH Q10

OOS Investigation Template

Structured Out-of-Specification investigation following FDA 2006 OOS Guidance with Phase I laboratory checklist and Phase II manufacturing review. GMP Trends and Assyro publish educational articles; this tool provides an interactive two-phase workflow with auto-save.

Quick Answer

An OOS (Out-of-Specification) result falls outside established acceptance criteria in a product specification or compendia. FDA 2006 OOS guidance requires a two-phase investigation: Phase I laboratory error assessment, then Phase II full investigation if no assignable lab error is found. OOS results cannot be invalidated without documented scientific justification; retesting without identified cause is prohibited. This template structures Phase I checklist, Phase II manufacturing review, disposition, and QA approval.

1
Phase I — Lab Investigation
2
Phase II — Full Investigation
0% complete
Section 1 — OOS Record Header
Section 2 — Phase I: Laboratory Error Checklist

Complete all items below. "Problem Found" means a laboratory error was identified. "No Problem Found" means this item is not the cause of the OOS result.

1 Was the correct test method / procedure used?
2 Was the reference standard within its expiry date and properly stored?
3 Was the instrument calibration current and within qualification period?
4 Was the sample properly prepared per the test method instructions?
5 Were all calculations reviewed and found to be free of errors?
6 Was instrument performance verified prior to and during analysis (e.g., SST)?
7 Were there any transcription, data entry, or data transfer errors identified?
8 Was the analysis environment suitable (temperature, humidity, vibration, etc.)?
9 Did the HPLC / instrument system suitability test pass per method criteria?
10 Was the column (or other consumable) used within its qualified lifespan?
Section 3 — Phase I Conclusion
Section 4 — Phase II: Full OOS Investigation

Extend the investigation beyond the laboratory. Review manufacturing, sampling, and authorize additional testing if appropriate.

Manufacturing Investigation
Was the correct batch record formula used?
Were correct raw materials (identity, quantity, certificate of analysis) used?
Was the correct equipment used and was it qualified / clean?
Were all critical process parameters within their specified ranges?
Sampling Investigation
Was sampling performed per the approved sampling procedure / plan?
Was the sample quantity adequate for the test?
Were sample storage conditions (temperature, light, humidity) correct?
Additional Testing
Section 5 — Disposition
Section 6 — Approvals

How to Use This Template

1
Record the OOS header—product, batch, test parameter, result, specification, analyst.
2
Complete all Phase I checklist items before concluding laboratory investigation.
3
Select Phase I finding: assignable lab error (document and authorize retest) or proceed to Phase II.
4
In Phase II, review manufacturing and sampling, record additional test statistics, write conclusion.
5
Set disposition, link CAPA if required, obtain QA approvals, and print/save PDF.

Pharma / GMP Context for QA Professionals

OOS investigations are among the highest-scrutiny QC activities during FDA inspections. 21 CFR 211.192 mandates investigation of any unexplained discrepancy or failure to meet specification. The 2006 FDA guidance remains the definitive framework—inspectors expect Phase I completion before Phase II expansion, documented hypothesis testing, and prohibition of testing into compliance.

Laboratory managers should segregate analyst responsibilities during investigation—the original analyst documents Phase I; QA provides independent review. Manufacturing involvement in Phase II requires production record review, equipment log assessment, and evaluation of other batches on shared lines. Statistical treatment of additional sample results must follow pre-approved protocols.

Confirmed OOS results typically trigger batch rejection and CAPA via the CAPA Template. Process-related findings may also require a Deviation Report. QC audit readiness uses the GMP Checklist Generator laboratory section.

Evidence and Sources

Frequently Asked Questions

An OOS (Out-of-Specification) result is any test result that falls outside the established acceptance criteria defined in the product specification, registration dossier, or official compendia (e.g., USP, EP). OOS results require formal investigation per FDA guidance and EU GMP. The investigation must determine whether the result represents a real product quality failure or is attributable to an identifiable laboratory error.
The FDA issued "Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production" guidance in October 2006 (finalizing a 1998 draft). It describes a two-phase structured investigation: Phase I (laboratory investigation to identify assignable laboratory error) and Phase II (full investigation including manufacturing review, sampling assessment, and additional testing). The guidance explicitly prohibits discarding OOS results without scientific justification.
OOS (Out-of-Specification) results exceed or fall below the defined acceptance limits. OOT (Out-of-Trend) results are within specification but show a statistically unexpected trend over time, detected through statistical process control or stability trending. OOT investigations are proactive (before failure) while OOS investigations are reactive (after failure). Both require investigation under GMP quality systems.
Yes, but only under strictly controlled conditions. An OOS result may be invalidated if—and only if—a specific, documented, assignable laboratory error is identified (e.g., wrong reference standard, confirmed calculation error, documented instrument malfunction). Statistical outlier tests and retesting without identified cause are not acceptable. The original OOS result must always be retained in the analytical record.
Phase II is required whenever Phase I laboratory investigation concludes with no assignable laboratory error. Phase II extends the investigation to include manufacturing records, raw material verification, sampling procedure assessment, environmental monitoring data, and authorized additional testing with pre-approved sampling plans.
Phase I is an immediate laboratory assessment to determine whether an assignable error caused the OOS result. The analyst and supervisor review method compliance, reference standards, calibration, sample preparation, calculations, system suitability, and data integrity. Phase I must be completed promptly—typically within 10 business days—before expanding to Phase II.
Testing into compliance means repeatedly retesting until a passing result is obtained without a documented assignable error—a practice explicitly prohibited by FDA OOS guidance. All OOS results, retests, and additional sample data must be reported and considered in batch disposition. Batch release requires a scientifically sound conclusion, not selective reporting of passing results.
Phase II may authorize testing additional samples from the same batch using a pre-approved plan defining sample count, statistical rationale, and acceptance criteria before testing begins. Averaging OOS with passing results to meet specification is generally not acceptable unless justified per guidance. Document mean, standard deviation, and %RSD of all results.
The Quality Unit (QA) must review and approve all OOS investigation conclusions before batch disposition—release, reject, rework, or retest. QA investigator and QA manager signatures document independent oversight. Regulatory affairs may be required when distributed batches are affected or field alert reporting thresholds are met.
Yes. FDA guidance and 21 CFR 211.192 require investigation to determine whether the OOS is associated with other batches of the same product or other products manufactured on shared equipment. Phase II manufacturing review should explicitly address potentially affected batches and retention sample testing if warranted.
A laboratory error is an assignable mistake in the analytical process (wrong standard, calculation error, instrument malfunction with evidence) that explains the OOS result. If a conclusive laboratory error is documented, the original OOS may be invalidated with scientific justification and retest authorized. If no assignable error exists, the OOS stands and Phase II investigates product/manufacturing causes.
OOS investigations feed the CAPA Template when systemic root causes are identified, the Deviation Template for process-related failures, Stability Schedule Generator for stability OOS context, and GMP Checklist Generator for QC laboratory audit readiness. RPN Calculator supports proactive FMEA before OOS events occur.

Related Tools

📄Deviation Report Template 📋CAPA Template ☰RPN Calculator ✅GMP Checklist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.